UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Twist Bioscience Corporation $TWST

Posted by Brian Himes on Sep 3rd, 2026

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 31.6% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 563,782 shares of the company’s stock after selling 260,194 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.90% of Twist Bioscience worth $58,002,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC increased its stake in Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after acquiring an additional 832,687 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after acquiring an additional 1,812,146 shares during the period. BlackRock Inc. purchased a new position in Twist Bioscience during the 2nd quarter valued at about $600,191,000. EdgePoint Investment Group Inc. increased its stake in shares of Twist Bioscience by 31.7% during the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after buying an additional 1,295,672 shares during the period. Finally, State Street Corp increased its position in Twist Bioscience by 17.4% during the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after purchasing an additional 538,755 shares during the period.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Barclays raised their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a research note on Monday, July 6th. Guggenheim reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 24th. Finally, Canaccord Genuity Group upped their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.30.

View Our Latest Report on Twist Bioscience

Twist Bioscience Price Performance

NASDAQ:TWST opened at $131.00 on Thursday. The business’s 50-day simple moving average is $109.76 and its two-hundred day simple moving average is $75.81. The stock has a market cap of $8.22 billion, a PE ratio of -59.01 and a beta of 2.22. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $155.44. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same quarter in the previous year, the company earned $0.33 earnings per share. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 2,399 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 291 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president owned 120,414 shares of the company’s stock, valued at $10,514,550.48. This represents a 0.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 193,099 shares of company stock valued at $24,026,581 over the last three months. Corporate insiders own 3.08% of the company’s stock.

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.